Statement of Changes in Beneficial Ownership (4)
10 December 2021 - 09:50AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Lecault Veronique |
2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc.
[
ABCL
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Operating Officer |
(Last)
(First)
(Middle)
C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/8/2021 |
(Street)
VANCOUVER, A1
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Shares | 12/8/2021 | | M | | 250000 | A | $0.19 | 1589333 | D | |
Common Shares | | | | | | | | 7155008 | I | See Footnote (1) |
Common Shares | | | | | | | | 273630 | I | See Footnote (2) |
Common Shares | | | | | | | | 61580 | I | By spouse |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Share Option (right to buy) | $0.19 | 12/8/2021 | | M | | | 250000 | (3) | 3/23/2027 | Common Shares | 250000 | $0.00 | 2524134 | D | |
Explanation of Responses: |
(1) | These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive
power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her
indirect pecuniary interest therein. |
(2) | These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial
ownership of such securities, except to the extent of her indirect pecuniary interest therein. |
(3) | The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Lecault Veronique C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER, A1 | X |
| Chief Operating Officer |
|
Signatures
|
/s/ Tryn Stimart, attorney-in-fact | | 12/9/2021 |
**Signature of Reporting Person | Date |
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Feb 2024 to Mar 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Mar 2023 to Mar 2024